Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:GNLX NASDAQ:GRCE NASDAQ:RANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$5.85+2.2%$6.07$4.50▼$11.54$127.47M2.3859,802 shs18,600 shsGNLXGenelux$3.08+0.7%$2.70$2.29▼$8.53$138.11M0.51227,717 shs193,602 shsGRCEGrace Therapeutics$2.42+3.9%$3.39$1.79▼$5.18$37.47M0.32530,429 shs225,106 shsRANIRani Therapeutics$0.99+3.9%$0.96$0.39▼$3.87$122.27M0.741.09 million shs1.01 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-2.55%-2.72%-10.89%-4.50%-35.03%GNLXGenelux+1.66%+4.44%+19.53%+5.88%+20.47%GRCEGrace Therapeutics-1.27%+6.88%+7.87%-43.45%-21.02%RANIRani Therapeutics+1.01%-12.84%+6.75%-31.16%+53.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$5.85+2.2%$6.07$4.50▼$11.54$127.47M2.3859,802 shs18,600 shsGNLXGenelux$3.08+0.7%$2.70$2.29▼$8.53$138.11M0.51227,717 shs193,602 shsGRCEGrace Therapeutics$2.42+3.9%$3.39$1.79▼$5.18$37.47M0.32530,429 shs225,106 shsRANIRani Therapeutics$0.99+3.9%$0.96$0.39▼$3.87$122.27M0.741.09 million shs1.01 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition-2.55%-2.72%-10.89%-4.50%-35.03%GNLXGenelux+1.66%+4.44%+19.53%+5.88%+20.47%GRCEGrace Therapeutics-1.27%+6.88%+7.87%-43.45%-21.02%RANIRani Therapeutics+1.01%-12.84%+6.75%-31.16%+53.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$16.00173.32% UpsideGNLXGenelux 2.50Moderate Buy$18.00484.42% UpsideGRCEGrace Therapeutics 2.00Hold$6.00147.73% UpsideRANIRani Therapeutics 2.60Moderate Buy$8.75786.52% UpsideCurrent Analyst Ratings BreakdownLatest GRCE, RANI, GNLX, and ACOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026ACOGAlpha Cognition HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.005/20/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.004/27/2026ACOGAlpha Cognition HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.004/24/2026GRCEGrace Therapeutics Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.004/24/2026GRCEGrace Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.004/21/2026GNLXGenelux Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026GRCEGrace Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ACOGAlpha Cognition Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.004/14/2026RANIRani Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.004/1/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $5.003/27/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha Cognition$10.83M11.77N/AN/A$2.64 per share2.22GNLXGenelux$8K17,263.40N/AN/A$0.51 per share6.04GRCEGrace TherapeuticsN/AN/AN/AN/A$4.86 per shareN/ARANIRani Therapeutics$3.17M38.58N/AN/A$0.29 per share3.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$20.67M-$1.35N/AN/AN/A-232.23%-58.35%-45.99%8/13/2026 (Estimated)GNLXGenelux-$32.15M-$0.85N/AN/AN/AN/A-174.55%-123.65%8/6/2026 (Estimated)GRCEGrace Therapeutics-$9.57M-$0.40N/AN/AN/AN/A-15.58%-14.51%6/22/2026 (Estimated)RANIRani Therapeutics-$29.67M-$0.41N/AN/AN/AN/A-206.46%-83.95%8/6/2026 (Estimated)Latest GRCE, RANI, GNLX, and ACOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/22/2026Q4 2026GRCEGrace Therapeutics-$0.24N/AN/AN/A$0.90 millionN/A5/15/2026Q1 2026RANIRani Therapeutics-$0.06-$0.04+$0.02-$0.04$1.13 million$1.71 million5/14/2026Q1 2026ACOGAlpha Cognition-$0.41-$0.37+$0.04-$0.32$3.42 million$3.53 million5/7/2026Q1 2026GNLXGenelux-$0.18-$0.20-$0.02-$0.20$0.01 millionN/A3/27/2026Q4 2025GNLXGenelux-$0.22-$0.24-$0.02-$0.24N/A$0.01 million3/26/2026Q4 2025ACOGAlpha Cognition-$0.27-$0.30-$0.03-$0.31$4.41 million$2.79 million3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 million3/19/2026Q4 2025GNLXGenelux-$0.22-$0.24-$0.02-$0.24N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A12.6411.52GNLXGeneluxN/A3.683.68GRCEGrace TherapeuticsN/A14.9614.96RANIRani TherapeuticsN/A3.403.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AGNLXGenelux37.33%GRCEGrace Therapeutics6.08%RANIRani Therapeutics30.19%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%GNLXGenelux7.50%GRCEGrace Therapeutics11.10%RANIRani Therapeutics26.73%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A21.77 million18.73 millionN/AGNLXGenelux1044.84 million41.48 millionNot OptionableGRCEGrace TherapeuticsN/A15.47 million13.76 millionN/ARANIRani Therapeutics110123.88 million90.77 millionOptionableGRCE, RANI, GNLX, and ACOG HeadlinesRecent News About These CompaniesRani Therapeutics Announces $20 Million Equity FinancingMay 27 at 6:50 AM | tipranks.comRani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesMay 26 at 8:00 AM | globenewswire.comRani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by AnalystsMay 21, 2026 | americanbankingnews.comRani Therapeutics Faces Nasdaq Bid Price Noncompliance NoticeMay 17, 2026 | theglobeandmail.comNasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid PriceMay 17, 2026 | tipranks.comRani Therapeutics (NASDAQ:RANI) Stock Rating Upgraded by Wall Street ZenMay 17, 2026 | americanbankingnews.comRani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO TransitionMay 15, 2026 | globenewswire.comRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comThis Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last YearMay 9, 2026 | finance.yahoo.comRani Therapeutics (NASDAQ:RANI) Downgraded by Wall Street Zen to "Sell"May 9, 2026 | marketbeat.comRani Therapeutics (RANI) Projected to Post Earnings on WednesdayMay 6, 2026 | marketbeat.comRani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14April 9, 2026 | msn.comRani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategyApril 9, 2026 | globenewswire.comThe Oral Delivery Revolution: Rani Therapeutics' Strategic PositionApril 2, 2026 | aktiencheck.deARani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16March 27, 2026 | msn.comRani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comRani Therapeutics Powers Ahead with Record-Breaking Q4 Results, Fueling Pipeline Growth and Platform ExpansionMarch 26, 2026 | news.themarketisopen.comNRani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate UpdateMarch 26, 2026 | globenewswire.comRani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationMarch 25, 2026 | globenewswire.comWhat To Expect From Rani Therapeutics Holdings Inc (RANI) Q4 2025 EarningsMarch 25, 2026 | finance.yahoo.comMaxim Group Keeps Their Buy Rating on Rani Therapeutics Holdings (RANI)March 21, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Alphabet’s Earnings Didn’t Just Beat—They Changed the StoryBy Ryan Hasson | April 30, 2026Atomic Dividends: Big Tech's New Energy BetBy Jeffrey Neal Johnson | May 5, 2026GRCE, RANI, GNLX, and ACOG Company DescriptionsAlpha Cognition NASDAQ:ACOG$5.85 +0.12 (+2.16%) As of 03:50 PM Eastern This is a fair market value price provided by Massive. Learn more.Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Genelux NASDAQ:GNLX$3.08 +0.02 (+0.65%) As of 03:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Grace Therapeutics NASDAQ:GRCE$2.42 +0.09 (+3.95%) As of 03:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Rani Therapeutics NASDAQ:RANI$0.99 +0.04 (+3.89%) As of 03:53 PM Eastern This is a fair market value price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas IREN Is Flipping the Switch from Bitcoin to AI This Quantum Computing Stock May Be Closer to a Breakout Than You Think Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It If the Market Rally Stalls, This ETF Can Insulate Portfolios RTX Is Set to Revolutionize Munitions Manufacturing Is Co-Diagnostics National Security’s Next Diagnostic Pick? Semtech’s Explosive Rally May Only Be Getting Started The Food Delivery War Just Entered Its Final Phase Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
